What is SpaceOAR Hydrogel?
Find Out How SpaceOAR
SpaceOAR Clinical Studies
Frequently Asked Questions
WALTHAM, Mass.–(BUSINESS WIRE) — Augmenix, Inc. announced the 3-year results from the SpaceOAR System Prostate Cancer US Pivotal Clinical Trial. These results were presented at the 2016 American Society for Radiation Oncology Annual Meeting in Boston, MA as a Late Breaking Abstract, an honor reserved for highly significant and timely findings in clinical oncology, radiobiology or medical physics.
Entitled “Continued Benefit to Rectal Separation for Prostate RT: Final Results of a Phase III Trial”, the study results presented by Daniel Hamstra, MD, PhD, a radiation oncologist at Texas Oncology in Irving, TX demonstrated significantly lower rectal toxicity and higher patient quality of life (QOL) scores when the SpaceOAR System was applied prior to radiotherapy as compared to the trial control patients.
2016 ASTRO Annual Meeting: Daniel A. Hamstra, MD, PhD, of Texas Oncology, discusses phase III findings on the use of an absorbable hydrogel spacer designed to decrease rectal toxicity and improve bowel quality of life for patients with prostate cancer. (Abstract LBA-6)
Following most forms of prostate cancer treatment, patient fertility is compromised.
If you or a loved one is undergoing treatment for prostate cancer, incorporating guidelines and tactics for maintaining nutrition should be part of the overall plan.
Surgery is recommended for BPH patients with severe symptoms and for those who medical therapies have not worked for.
in Chicago, IL